Peripheral and tumor immune correlates in patients with advanced melanoma treated with combination nivolumab (anti-PD-1, BMS-936558, ONO-4538) and ipilimumab.
Margaret K. Callahan
Research Funding - Bristol-Myers Squibb
Christine E. Horak
Employment or Leadership Position - Bristol-Myers Squibb
Stock Ownership - Bristol-Myers Squibb
Michael A. Curran
No relevant relationships to disclose
Travis Hollman
No relevant relationships to disclose
David A. Schaer
No relevant relationships to disclose
Jianda Yuan
No relevant relationships to disclose
Alexander M. Lesokhin
Research Funding - Bristol-Myers Squibb
Shigehisa Kitano
No relevant relationships to disclose
Quan Hong
Employment or Leadership Position - Bristol-Myers Squibb
Stock Ownership - Bristol-Myers Squibb
Charlotte Eielson Ariyan
Consultant or Advisory Role - Bristol-Myers Squibb
Klaus J. Busam
No relevant relationships to disclose
William Feely
Employment or Leadership Position - Bristol-Myers Squibb
Maria Jure-Kunkel
Employment or Leadership Position - Bristol-Myers Squibb
Stock Ownership - Bristol-Myers Squibb
Joseph Grosso
Employment or Leadership Position - Bristol-Myers Squibb
Stock Ownership - Bristol-Myers Squibb
Jason S. Simon
Employment or Leadership Position - Bristol-Myers Squibb
Stock Ownership - Bristol-Myers Squibb
Alan J. Korman
Employment or Leadership Position - Bristol-Myers Squibb
Stock Ownership - Bristol-Myers Squibb
Jon M. Wigginton
Employment or Leadership Position - Bristol-Myers Squibb
Stock Ownership - Bristol-Myers Squibb
Ashok Kumar Gupta
Employment or Leadership Position - Bristol-Myers Squibb
Stock Ownership - Bristol-Myers Squibb
Mario Sznol
No relevant relationships to disclose
Jedd D. Wolchok
Consultant or Advisory Role - Bristol-Myers Squibb
Research Funding - Bristol-Myers Squibb